Company signals · Biotech & Pharma
Ratio Therapeutics
2 signals in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: MitchelLake's Talent Market Index sits at 104.6 (Hot), down 1.9 on the prior month; Americas hiring signal is running rising (+2.1pts).
Ratio Therapeutics: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Americas signal flow; 2 tracked across 63 days.
Signals at Ratio Therapeutics
Capital Raising
AmericasRatio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Leadership read: Ratio Therapeutics's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.
curated · 2026-07-31 · context →
Partnership
AmericasRatio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Leadership read: Alliances broaden the commercial surface, and the leadership need follows. Ratio Therapeutics's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Americas, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.
curated · 2026-05-29 · context →
More signals across Biotech & Pharma
Partnership · Americas
Bristol Myers Squibb →Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Partnership · Americas
BioDuro →BioDuro forms strategic partnership with CTI Biotechnology to create integrated platform from discovery to IND submission for preclinical drug development
Leadership Change · Americas
Flagship Pioneering →Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).
Leadership Change · Americas
Teva Pharmaceuticals →Teva Pharmaceuticals CEO Richard Francis discusses Q2 earnings, drug pipeline, and the company's direct listing on NYSE. Signals leadership visibility and capital market transition.
Product Launch · Americas
Amgen →Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.
Intelligence powered by Autonodal ↗